Efficacy, Safety and Tolerability of Valsartan and Hydrochlorothiazide Compared to Valsartan and Amlodipine in Stage 2 Hypertension
DOI:
https://doi.org/10.53685/jshmdc.v3i1.94Abstract
Background: Hypertension is a growing medical and public health issue. The United States and European treatment guidelines have been issued to attain smooth control of hypertension in various categories of patients. It is a need of time to unveil safe combination therapies in various populations.
Objectives: (i) To determine the efficacy of valsartan and hydrochlorothiazide versus valsartan and amlodipine (ii) To determine the safety and tolerability of both combinations.
Materials & Methods: This experimental study was conducted at Shalamar Hospital Lahore. 126 patients with stage 2 hypertension were recruited from the medical outdoor of Shalamar Hospital Lahore after getting informed consent. In group A, 63 patients were given valsartan and hydrochlorothiazide. In group B, 63 patients were given valsartan and amlodipine. Blood pressure (BP) of both study groups was recorded on day zero, 2nd, 4th, and 8th weeks and the readings were entered on a Proforma. The efficacy of drug combinations was accessed in both groups by recording the change in mean systolic blood pressure (MSBP) and mean diastolic blood pressure (MDBP). The safety and tolerability of the drug combinations were assessed in terms of side effects and laboratory findings.
Results: In group A, there was a 39±7mmzHg and 18±1mmHg decrease in MSBP and MDBP, respectively, from baseline BP. In group B, there was a 26.7±4mmHg and 14±2 mmHg decrease in MSBP and MDBP, respectively, from baseline BP. Both combinations were safe, and no significant difference in the efficacy of both combinations was observed after 8-week of treatment.
Conclusion: Both combinations are effective for control of BP, but the valsartan and hydrochlorothiazide combination (group A) appears to have better tolerability and greater effect in decreasing BP as compared to the combination of valsartan and amlodipine (group B), although this difference is not statistically significant.
References
Hong D, Shan W. Improvement in hypertension management with pharmacological and non-pharmacological approaches: Current Perspectives. Curr Pharm Des. 2021; 27(4): 548-555. doi:10.2174/138161 282666620092215304 5
Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) Eur Heart J. 2018; 39(33): 3021–3104.doi:10.1097/HJH.0000000000001 940.
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Cheryl DH, et al. Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018; 71 (19): 127–e248.doi:10.1161/HYP.000000000000 0066.
Rochlani Y, Khan MK, Banach M, Aronow WS. Are two drugs better than one? A review of combination therapies for hypertension, Expert Opin Pharmacother. 2017; 18(4): 377-386. doi: 10.1080/14656566.2017.1288719
Volpe M, Tocci G. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vasc Health Risk Manag. 2012; 8: 371-380. doi: 10.2147/VRM .S28359.
Buscemi S, Buscemi C, Borzì AM, Cosentino L, Rosafio G, Randazzo C, et al. Metabolic and cardiovascular effects of switching Thiazides to Amlodipine in hypertensive patients with and without Type 2 Diabetes (the Diuretics and Diabetes Control Study. Metab Syndr Relat Disord. 2020; 18(2): 110-118.doi:1 0.1089/met. 2019.0099.
Cho EJ, Lee HY, Sung KC, Park S, Sohn IS, Park CG, et al. Comparison of 24-Hour Ambulatory Central Blood Pressure Reduction Efficacy Between Fixed Amlodipine or Up-Titrated Hydrochlorothiazide Plus Losartan: The K- Central Study. Am J Hypertens. 2019; 32(10): 992-1002. doi: 10.1 093/ajh/hp z050
Kensuke K, Ryuji T, Tatsuro I, Kenta M, Tomoyuki Y, Kenichi H. Comparison of telmisartan/amlodipine and telmisartan/ hydrochlorothiazide in the treatment of Japanese patients with uncontrolled hypertension. Blood Press Monit. 2016; 21(3): 171-177. doi: 10.1097/MBP.00 0000000000017 2.
Ojji DB, Mayosi B, Francis V, Badri M, Cornelius V, Smythe W, et al. Comparison of dual therapies for lowering blood pressure in Black Africans. N Engl J Med. 2019; 380 (25):24292439.doi:10.1056/NEJMoa1901113.
Flight L, Julious SA. A practical guide to sample size calculations: non-inferiority and equivalence trials. Pharm Stat. 2016; 15(1): 80-89. doi:10.1002/ pst.1716.
Stergiou G, Palatini P, Asmar R, de la Sierra A, Myers M, Shennan A, et al. Blood pressure measurement and hypertension diagnosis in the 2017 US guidelines: first things first. Hypertension. 2018; 71(6): 963965.doi.org/10.11 61/HYPERTENSIONAHA.118.10853
Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril/ valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertens Res. 2022; 45(5): 824-833. doi: 10.1038/s41440-021-00819-7
Humagain S, Koju R. Efficacy of different antihypertensive drugs among newly diagnosed hypertensive patient in Dhulikhel Hospital. Kathmandu Univ Med J. 2015; 13(51):212215. doi:10.3126/kumj.v13i3.16806.
Lv Y, Zou Z, Chen GM, Jia HX, Zhong J, Fang WW. Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials. Blood Press Monit. 2010; 15(4): 195-204.
Poldermans D, Glazes R, Kargiannis S, Wernsing M, Kaczor J, Chiang YT, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage-2 hypertension. Clin Ther. 2007; 29(2): 279-289.doi:10.1016/j.clinthera.2007.02.003.
Dar MH, Falah SF, khan I, khan A, Ali U. Efficacy of valsartan plus amlodipine versus valsartan plus hydrochlorothiazide for control of moderate to severe hypertension: a randomized controlled trial. Pak Heart J. 2017; 50(01): 39-44.
Zappe D, Papst CC, Ferber P, PROMPT Investigators. Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control. Vasc Health Risk Manag. 2009; 5: 883–892. doi: 10.2147/vhrm.s8062
De la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. Journal of human hypertension. 2009; (8): 503-511. doi: 10.2147/vhrm.s8062
Weir MR, Ferdinand KC, Flack JM, Jamerson KA, Daley W, Zelenkofske S. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. Hypertension. 2005; 46(3): 508-513.doi:10.1161/01.HYP.0000180457.8248 3.6b
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Abdul karim, Sarwat Iqbal, Shabbir Ali Bhatti, Mujeeb-ur-Rehman Abid, Naveed Iqbal, Asad Ejaz
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
Non Commercial — You may not use the material for commercial purposes.
-
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a 
